Kev Pom Zoo ntawm HIBRUKA (Orelabrutinib) rau Kev Kho Mob Marginal Zone Lymphoma hauv Singapore

Thaum Lub Cuaj Hlis 8, 2025, InnoCare Pharma tshaj tawm tias HIBRUKA (orelabrutinib) tau txais kev pom zoo los ntawm Lub Chaw Haujlwm Saib Xyuas Kev Noj Qab Haus Huv (HSA) ntawm Singapore rau kev kho mob rau cov neeg laus uas muaj mob lymphoma rov qab los lossis tsis kho tau (R/R MZL).

Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.

Xov Tooj: 4008803716

WeChat ID: 17801183037

Email：myimmnet@163.com

Marginal zone lymphoma (MZL) yog ib hom kab mob B-cell non-Hodgkin's lymphoma (NHL) uas feem ntau cuam tshuam rau cov neeg mob hnub nyoog nruab nrab thiab cov neeg laus. Txhua xyoo tus kab mob MZL nce siab thoob ntiaj teb. Tom qab kev kho mob thawj kab, cov neeg mob uas muaj R/R MZL tsis muaj kev kho mob zoo.

Thaum Lub Plaub Hlis 2025, orelabrutinib tau txais kev pom zoo hauv Suav teb rau kev kho mob thawj kab ntawm cov neeg mob uas muaj mob leukemia lymphocytic (CLL) / lymphocytic lymphoma me me (SLL). Orelabrutinib kuj tau txais kev pom zoo rau kev kho mob ntawm peb lwm yam cim hauv Suav teb, suav nrog relapsed thiab refractory (R/R) CLL/SLL, r/r mantle cell lymphoma (R/R MCL) thiab r/r marginal zone lymphoma (R/R MZL), tag nrho cov no tau raug suav nrog hauv Daim Ntawv Teev Tshuaj Rov Qab Nyiaj Hauv Tebchaws Suav.

Qhov Kev Ua Haujlwm Zoo, Kev Nyab Xeeb, thiab Kev Muaj Peev Xwm ntawm Orelabrutinib Plus Obinutuzumab hauv Kev Kho Mob Systemic-Naive Marginal Zone Lymphoma: Ib Txoj Kev Tshawb Fawb Txog Cohort tau qhia tias Thoob plaws tag nrho kev tshawb fawb thiab thaum lub sijhawm kho mob induction, qhov feem pua ​​​​​​ntawm kev teb tag nrho (ORR) yog 100%. Peb tus neeg mob uas muaj kev teb ib nrab (PR) tom qab kev kho mob induction tau ua tiav kev teb tiav (CR) thaum lub sijhawm txij nkawm.

Cov kev ntsuam xyuas ADCC qhia tau tias orelabrutinib ua ke nrog obinutuzumab regimen ua rau muaj kev teb ADCC nquag tshaj plaws hauv TMD-8 thiab REC-1 cell lines.

Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.

Xov Tooj: 4008803716

WeChat ID: 17801183037

Email：myimmnet@163.com